Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: tofacitinib, peficitinib, ritlecitinib tosylate +17 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 2,439 | 0.91 |
| pathways Reactome | 11 pathways; mostly immune signalling | 0.90 |
Knock down and overexpress JAK3 in a dopamine neuron, astrocyte and microglia tri-culture; measure IL-1β and TNF release and surface HLA-DR and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of JAK3 in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- JAK3 in dopamine neurons, braak-0.16 (p 0.685) → -0.68 (p 0.045)receipt 7535
Swarm cases
receipt 7535: JAK3 in dopamine neurons, braak
- power
- full sample -0.48 (p 0.043, n 18), 95% CI -0.77 to -0.02. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.55 (p 0.019, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.68 (p 0.0019, n 18). not the mix.
- skeptic
- leave-one-out range -0.59 to -0.42, sign flips 0; without severely affected donors -0.48 (p 0.043, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for JAK3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts